These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32717302)

  • 1. Intravitreal hydrogels for sustained release of therapeutic proteins.
    Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
    J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
    Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
    Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biocompatible reverse thermoresponsive polymer for ocular drug delivery.
    Balachandra A; Chan EC; Paul JP; Ng S; Chrysostomou V; Ngo S; Mayadunne R; van Wijngaarden P
    Drug Deliv; 2019 Dec; 26(1):343-353. PubMed ID: 30905169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
    Alshaikh RA; Waeber C; Ryan KB
    Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal therapeutic nanoparticles for age-related macular degeneration: Design principles, progress and opportunities.
    Zhang Y; Watson S; Ramaswamy Y; Singh G
    Adv Colloid Interface Sci; 2024 Jul; 329():103200. PubMed ID: 38788306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.
    Bisht R; Mandal A; Jaiswal JK; Rupenthal ID
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Mar; 10(2):. PubMed ID: 28425224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease.
    Xie B; Jin L; Luo Z; Yu J; Shi S; Zhang Z; Shen M; Chen H; Li X; Song Z
    Int J Pharm; 2015 Jul; 490(1-2):375-83. PubMed ID: 26027491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled release strategy designed for intravitreal protein delivery to the retina.
    Delplace V; Ortin-Martinez A; Tsai ELS; Amin AN; Wallace V; Shoichet MS
    J Control Release; 2019 Jan; 293():10-20. PubMed ID: 30419267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
    Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable Microspheres as Intravitreal Delivery Systems for Prolonged Drug Release. What is their Eminence in the Nanoparticle Era?
    Gavini E; Bonferoni MC; Rassu G; Obinu A; Ferrari F; Giunchedi P
    Curr Drug Deliv; 2018; 15(7):930-940. PubMed ID: 29484995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.
    Chacin Ruiz EA; Swindle-Reilly KE; Ford Versypt AN
    J Control Release; 2023 Nov; 363():464-483. PubMed ID: 37774953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in intraocular drug delivery systems.
    Yasukawa T; Tabata Y; Kimura H; Ogura Y
    Recent Pat Drug Deliv Formul; 2011 Jan; 5(1):1-10. PubMed ID: 21143129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ antibody-loaded hydrogel for intravitreal delivery.
    Awwad S; Abubakre A; Angkawinitwong U; Khaw PT; Brocchini S
    Eur J Pharm Sci; 2019 Sep; 137():104993. PubMed ID: 31302214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotherapies for the Treatment of Age-Related Macular Degeneration (AMD) Disease: Recent Advancements and Challenges.
    Rapalli VK; Gorantla S; Waghule T; Mahmood A; Singh PP; Dubey SK; Saha RN; Singhvi G
    Recent Pat Drug Deliv Formul; 2019; 13(4):283-290. PubMed ID: 31951173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress of ocular sustained-release corticosteroid delivery systems].
    Liu ZY; Chen YY
    Zhonghua Yan Ke Za Zhi; 2018 Feb; 54(2):154-160. PubMed ID: 29429302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds.
    Rafael D; Guerrero M; Marican A; Arango D; Sarmento B; Ferrer R; Durán-Lara EF; Clark SJ; Schwartz S
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.